Recent transcriptomic and single-cell studies have identified IL27RA and TMEM71 as immune-related biomarkers predictive of therapeutic response in TNBC.[17,18] Incorporating these markers into diagnostic algorithms could significantly improve discrimination between second primary malignancies and metastatic disease, which is a critical distinction underscored by the current case of a chest wall mass developing post-TNBC. The gene discussed is TMEM71; the disease is metastatic neoplasm.